Immunovant (IMVT) Long-Term Investments (2019)
Immunovant (IMVT) posted Long-Term Investments of $116.0 million for Q3 2019, up 0.59% on a QoQ basis from $115.3 million in Q2 2019.
Immunovant (IMVT) Long-Term Investments (2019) Analysis & Trends
Immunovant's Long-Term Investments history runs 1 years deep, the most recent figure standing at $116.0 million for Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 505,194.89 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Immunovant | 7.17 Bn | 7.17 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 116.02 Mn |
| Jun 30, 2019 | 115.34 Mn |